Risk Factors for Autoimmune Diseases Development After Thrombotic Thrombocytopenic Purpura-Reference-Cited by-同舟云学术

Risk Factors for Autoimmune Diseases Development After Thrombotic Thrombocytopenic Purpura

Published:2015-10 Issue:42 Volume:94 Page:e1598
ISSN:0025-7974
Container-title:Medicine
language:en
Short-container-title:

Author:

Roriz Mélanie,Landais Mickael,Desprez Jonathan,Barbet Christelle,Azoulay Elie,Galicier Lionel,Wynckel Alain,Baudel Jean-Luc,Provôt François,Pène Frédéric,Mira Jean-Paul,Presne Claire,Poullin Pascale,Delmas Yahsou,Kanouni Tarik,Seguin Amélie,Mousson Christiane,Servais Aude,Bordessoule Dominique,Perez Pierre,Chauveau Dominique,Veyradier Agnès,Halimi Jean-Michel,Hamidou Mohamed,Coppo Paul

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

General Medicine

Reference44 articles.

1. Thrombotic thrombocytopenic purpura: basic pathophysiology and therapeutic strategies.;Crawley;Hematology Am Soc Educ Program,2013

2. Evaluation of patients with microangiopathic hemolytic anemia and thrombocytopenia.;George;Semin Thromb Hemost,2013

3. Syndromes of microangiopathy.;George;N Eng J Med,2014

4. Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura.;Tsai;N Engl J Med,1998

5. Von Willebrand factor cleaving protease (ADAMTS13) in thrombotic thrombocytopenic disorders: a severely deficient activity is specific for thrombotic thrombocytopenic purpura.;Bianchi;Blood,2002

Cited by 60 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Clinical, biological, prognostic characteristics of patients with immune-mediated thrombotic thrombocytopenic purpura and Sjögren’s disease;RMD Open;2024-08

2. Management of Essential Thrombocythemia in a Patient With a History of Thrombotic Thrombocytopenic Purpura;Cureus;2024-04-06

3. Autoimmune thrombotic thrombocytopenic purpura associated with disseminated sarcoidosis: A case report;eJHaem;2024-02

4. Hereditary Thrombotic Thrombocytopenic Purpura;Genes;2023-10-18

5. Thrombotic thrombocytopenic purpura that developed 3 years after systemic lupus erythematosus had remitted with rituximab therapy;Modern Rheumatology Case Reports;2023-06-10